- Home
- HERZ vs PLUR Comparison
HERZ vs PLUR Comparison
Compare HERZ & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | PLUR |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 28.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HERZ | PLUR |
|---|---|---|
| Price | $17.61 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | N/A | ★ 13.2K |
| Earning Date | N/A | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,339,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 97.49 |
| 52 Week Low | N/A | $2.82 |
| 52 Week High | N/A | $7.13 |
Technical Indicators
Market Signals| Indicator | HERZ | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 92.44 | 51.88 |
| Support Level | $17.92 | $3.30 |
| Resistance Level | $18.53 | $3.90 |
| Average True Range (ATR) | 0.41 | 0.20 |
| MACD | 1.93 | 0.02 |
| Stochastic Oscillator | 95.36 | 28.33 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.